Less than 1 year = 48% of adults or 69% of the eligible market 1-2 years = 12% of adults or 16% of the eligible market 2 years plus = 11% of adults or 15% of the eligible market (29 million adults) As with most GPG brands, the bulk of initial prescriptions will go to folks who do not maintain a weekly injection discipline for many reasons
This lower ceiling reflects that blood sugar control typically achieves therapeutic targets before the 2.4 mg weight management dose is needed
The FDA has warned patients to be cautious with unapproved GLP-1 products and notes that compounded drugs are not reviewed by the agency for safety, effectiveness, or quality before marketing
PMID: 1675986
This was really the first study to address this question, and I think this exciting new area will have more studies coming out in the next 10 to 15 years
Gantz I, Muraoka A, Yang YK, Samuelson LC, Zimmerman EM, Cook H, Yamada T